Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

@article{Calabresi2014PegylatedIB,
  title={Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study},
  author={Peter A. Calabresi and Bernd C. Kieseier and Douglas L. Arnold and Laura Balcer and Alexey Boyko and Jean Pelletier and Shifang Liu and Ying Zhu and Ali Seddighzadeh and Serena Hung and Aaron Deykin},
  journal={The Lancet Neurology},
  year={2014},
  volume={13},
  pages={657-665}
}

Figures and Tables from this paper

Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU
TLDR
Peginterferon beta-1a (Plegridy™) extends the options currently available to treat adults with relapsing–remitting multiple sclerosis (RRMS) and provides potential compliance advantages over non-pegylated interferonbeta formulations that require more frequent administration.
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
TLDR
The available data support the use of PEG-IFN as a suitable therapeutic option in patients with relapsing-remitting multiple sclerosis and good efficacy and a good safety profile.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
TLDR
With similar efficacy compared to other RRMS treatments in terms of annualized relapse rate and 3- and 6-month CDP, a promising safety profile, and up to 93% reduction in number of injections, PEG-IFN every 2 weeks offers a valuable alternative treatment option for patients with RRMS.
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
TLDR
Although for both doses some differences in the point estimates for ARR were noted among the subgroups, considerable overlap in the confidence intervals suggested that the efficacy of peginterferon beta-1a is similar in all patients irrespective of gender, age, body weight, geographical region, and disease activity at initiation of treatment.
Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority
TLDR
A calendar with CW was non-inferior than FR at the beginning of IFN-b therapy, and may not affect the long-term outcome, as compared with a calendar with FR.
Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
TLDR
Peginterferon beta-1a has the potential to prevent/delay worsening of disability in patients with relapsing–remitting multiple sclerosis and was associated with improved functional status and health-related quality of life (HRQoL).
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
TLDR
Results from the ADVANCE extension study, ATTAIN, confirm the favorable long-term safety and tolerability profile of peginterferon beta-1a in patients with RRMS and provide additional evidence for the clinical and radiological benefits associated with this therapy.
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
TLDR
The PK profile of peginterferon beta-1a did not change over time or between dosing regimens, and neopterin elevation was sustained for 10−14 days following each dose, indicating doubled cumulative duration of pharmacological activity for dosing every 2 weeks vs. every 4 weeks.
Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
TLDR
Long-term treatment with peginterferon beta-1a improves clinical outcomes, while its cost profile makes it either dominant or cost-effective compared with other self-injectable DMTs for the treatment of RRMS in Scotland.
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
TLDR
Switching relapsing multiple sclerosis patients to SC peginterferon beta-1a from other IFN therapies significantly improved treatment satisfaction and convenience.
...
...

References

SHOWING 1-10 OF 35 REFERENCES
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
TLDR
Copolymer 1 (Copaxone) was studied in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis and significantly more patients receiving copolym 1 were found to have improved and more receiving placebo worsened.
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
TLDR
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
TLDR
It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
TLDR
The data support the continued clinical development of PEG‐IFN beta‐1a as a potentially effective treatment for patients with relapsing multiple sclerosis.
Defining interferon beta response status in multiple sclerosis patients.
TLDR
It was found that subgroups with high on-study relapse numbers had more disease progression, differences between responder subgroups were similar in the IFN-beta1a and placebo arms and Baseline characteristics failed to account for differential outcome.
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
TLDR
Patients on IM IFNβ-1a had fewer ISRs and were less likely to switch therapies than patients on other therapies, and this study may have implications in selecting initial therapy or, for patients considering switching or discontinuing therapy because of ISRs, selecting an alternative option.
Defining interferon β response status in multiple sclerosis patients
TLDR
It was found that subgroups with high on‐study relapse numbers had more disease progression, differences between responder subgroups were similar in the IFN‐β1a and placebo arms, and Baseline characteristics failed to account for differential outcome.
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
  • F. Patti
  • Medicine, Psychology
    Patient preference and adherence
  • 2010
TLDR
The barriers to adherence to MS therapies are summarized, and patient management strategies that can be employed to encourage adherence are discussed, including the development of orally administered drugs which may enhance adherence.
...
...